Erschienen in:
29.10.2023 | Hepatobiliary Tumors
The Short- and Long-Term Surgical Results of Consecutive Hepatopancreaticoduodenectomy for Wide-Spread Biliary Malignancy
verfasst von:
Yasunori Yoshimi, MD, Takehiro Noji, MD, PhD, Keisuke Okamura, MD, PhD, Kimitaka Tanaka, MD, PhD, Aya Matsui, MD, PhD, Yoshitsugu Nakanishi, MD, PhD, Toshimichi Asano, MD, PhD, Toru Nakamura, MD, PhD, Takahiro Tsuchikawa, MD, PhD, Yasuyuki Kawamoto, MD, PhD, Kazuaki Harada, MD, PhD, Kanako Fuyama, MASc, Kazuhumi Okada, MPH, Satoshi Hirano, MD, PhD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 1/2024
Einloggen, um Zugang zu erhalten
Abstract
Background
Cancer-free resection (R0) is one of the most important factors for the long-term survival of biliary carcinoma. For some patients with widespread invasive cancer located between the hilar and intrapancreatic bile duct, hepatopancreaticoduodenectomy (HPD) is considered a radical surgery for R0 resection. However, HPD is associated with high morbidity and mortality rates. Furthermore, previous reports have not shown lymph node metastasis (LNM) status, such as the location or number, which could influence the prognosis after HPD. In this study, first, we explored the prognostic factors for survival, and second, we evaluated whether the LNM status (number and location of LNM) would influence the decision on surgical indications in patients with widely spread biliary malignancy.
Methods
We retrospectively reviewed the medical records of 54 patients who underwent HPD with hepatectomy in ≥2 liver sectors from January 2003 to December 2021 (HPD-G). We also evaluated 54 unresectable perihilar cholangiocarcinoma patients who underwent chemotherapy from January 2010 to December 2021 (CTx-G).
Results
R0 resection was performed in 48 patients (89%). The median survival time (MST) and 5-year overall survival rate of the HPD-G and CTx-G groups were 36.9 months and 31.1%, and 19.6 months and 0%, respectively. Univariate and multivariate analyses showed that pathological portal vein involvement was an independent prognostic factor for survival (MST: 18.9 months). Additionally, patients with peripancreatic LNM had worse prognoses (MST: 13.3 months) than CTx-G.
Conclusions
Patients with peripancreatic LNM or PV invasion might be advised to be excluded from surgery-first indications for HPD.